A total of three targets have been selected for portfolio entry in the collaboration to date, with the potential to generate further future development milestones and sales-based royalty revenues for BenevolentAI
They are GQ1005, an ADC with an excellent bystander killing effect, and GQ1007, a first-in-class antibody-immune-agonist-conjugate (AIAC) both with global intellectual property rights
Huntington Medical Research Institutes present first-of-its-kind study examining impact of erectile dysfunction drugs on major adverse cardiovascular events and mortality
The treatment of chorea associated with HD is within the scope of this Orphan Drug Designation
CB03 is a candidate drug for the treatment of refractory epilepsy, independently developed by Zhimeng
The capex for FY22 stood at Rs 145 crore and is expected to be in the range of Rs 250-350 crore for the entire FY23 which would be funded through a mix of internal accruals and debt
The inspection report contains no 'critical' observations and only one of the deficiencies is categorized as 'major' which is being addressed expeditiously in consultation with the regulatory agency
The procedures have been performed by Dr. Kaushal Pandey at P.D. Hinduja Hospital in Mumbai, India
The facility is among 12 centres established worldwide, and the first in Asia
The companies expect to complete the submission of the NDA for treatment of MDD in the second half of 2022; associated filing for postpartum depression is anticipated in the first half of 2023
Subscribe To Our Newsletter & Stay Updated
